The highest proportion of TP53 mutations was detected in AML cases (57.69%), followed by 33.33% in MDS-IB samples and 17.95% in MDS-LB samples, all having TP53 gene aberrations. The gene discussed is TP53; the disease is myelodysplastic syndrome.